Mastitis Market Summary
According to MRFR analysis, the Mastitis Market size was valued at USD 27.58 Billion in 2024. The market is projected to grow from USD 32.20 Billion in 2025 to USD 151.24 Billion by 2035, exhibiting a CAGR of 16.73% during the forecast period 2025-2035.North America led the market with over 44.96% share, generating around USD 12.4 Billion in revenue.
The Mastitis Market is growing due to increasing prevalence of breast infections among lactating women and rising awareness of early diagnosis and treatment. Key trends include advancements in antibiotic therapies, improved diagnostic methods, and growing focus on maternal healthcare, supporting better disease management and reducing complications globally.
According to the World Health Organization, mastitis affects up to 10% of breastfeeding women, emphasizing the need for effective diagnosis and treatment strategies.
Key Market Trends & Highlights
The Mastitis Market is experiencing a dynamic shift driven by technological advancements and changing consumer demands.
- Technological advancements in diagnostics are enhancing the detection and management of mastitis in both bovine and human populations.
- North America remains the largest market for mastitis treatments, while the Asia-Pacific region is emerging as the fastest-growing market.
- Bovine mastitis treatment, particularly through antibiotics, continues to dominate the market, whereas human mastitis solutions are witnessing rapid growth.
- The rising incidence of mastitis in dairy cattle and growing awareness of animal health are key drivers propelling market expansion.
Market Size & Forecast
| 2024 Market Size | 27.58 (USD Billion) |
| 2035 Market Size | 151.24 (USD Billion) |
| CAGR (2025 - 2035) | 16.73% |
Major Players
Companies such as Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Cegelec (FR), Vetoquinol (FR), Huvepharma (BG), Phibro Animal Health (US), Dechra Pharmaceuticals (GB) are some of the major participants in the global market.